A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies

References

• Banerjee S, Smith IE. Management of small HER2-positive breast cancers. Lancet Oncol. 11(12), 1193–1199 (2010).
   PubMed Web of Science ®Google Scholar
• Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin. Adv. Hematol. Oncol. 7(1), 45–53, 64 (2009).
   PubMedGoogle Scholar
• Gerber DE. Targeted therapies: a new generation of cancer treatments. Am. Fam. Physician 77(3), 311–319 (2008).
   PubMed Web of Science ®Google Scholar
• Pollack A. A push to tie new drugs to testing. New York Times 26 December (2011).
   Google Scholar
• Smith TJ, Hillner BE. Bending the cost curve in cancer care. N. Engl. J. Med. 364(21), 2060–2065 (2011).
   PubMed Web of Science ®Google Scholar
• Schulman KA, Tunis SR. A policy approach to the development of molecular diagnostic tests. Nat. Biotechnol. 28(11), 1157–1159 (2010).
   Web of Science ®Google Scholar
• Atherly AJ, Camidge DR. The cost–effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer 106(6), 1100–1106 (2012).
   PubMed Web of Science ®Google Scholar
• Mittmann N, Au HJ, Tu D et al.; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group. Prospective cost–effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J. Natl Cancer Inst. 101(17), 1182–1192 (2009).
   PubMedGoogle Scholar
• Horgan AM, Bradbury PA, Amir E et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann. Oncol. 22(8), 1805–1811 (2011).
   PubMed Web of Science ®Google Scholar
• Hedden L, O’Reilly S, Lohrisch C et al. Assessing the real-world cost–effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist 17(2), 164–171 (2012).
   PubMed Web of Science ®Google Scholar
• Gaultney JG, Sanhueza E, Janssen JJ, Redekop WK, Uyl-de Groot CA. Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics 12(3), 411–421 (2011).
   Google Scholar
• de Lima Lopes G Jr, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost–effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118(4), 1032–1039 (2012).
   PubMed Web of Science ®Google Scholar
• Lidgren M, Wilking N, Jönsson B, Rehnberg C. Cost–effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol. 47(6), 1018–1028 (2008).
   PubMed Web of Science ®Google Scholar
• Meunnig P. Cost–Effectiveness Analysis in Health – A Practical Approach (2nd Edition). Jossey-Bass, CA, USA (2008).
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost–Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Banoo S, Bell D, Bossuyt P. Evaluation of diagnostic tests for infectious diseases: general principles. Nat. Rev. Microbiol. 8(Suppl. 12), S17–S29 (2010).
   PubMedGoogle Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 25(6), 625–633 (2007).
   PubMed Web of Science ®Google Scholar
• Donaldson C, Baker R, Mason H et al. The social value of a QALY: raising the bar or barring the raise? BMC Health Serv. Res. 11, 8 (2011).
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br. Med. Bull. 96, 5–21 (2010).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol. 199(4), 418–423 (2003).
   PubMed Web of Science ®Google Scholar
• Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum. Pathol. 36(3), 250–261 (2005).
   PubMed Web of Science ®Google Scholar
• Press MF, Sauter G, Bernstein L et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 11(18), 6598–6607 (2005).
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN et al.; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118–145 (2007).
   PubMed Web of Science ®Google Scholar
• Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S. Quantitative PCR and HER2 testing in breast cancer: a technical and cost–effectiveness analysis. Am. J. Clin. Pathol. 129(4), 563–570 (2008).
   PubMedGoogle Scholar
• Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM. Cost–effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int. J. Cancer 131(2), 438–445 (2012).
   PubMed Web of Science ®Google Scholar
• Engstrom PF, Arnoletti JP, Benson AB 3rd et al.; National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J. Natl Compr. Canc. Netw. 7(8), 778–831 (2009).
   PubMed Web of Science ®Google Scholar
• Schmiegel W, Reinacher-Schick A, Arnold D et al. Update S3-guideline ‘colorectal cancer’ 2008. Z. Gastroenterol. 46(8), 799–840 (2008).
   PubMedGoogle Scholar
• Schubert C. Cancer drugs find a companion with new diagnostic tests. Nat. Med. 17(10), 1157 (2011).
   PubMed Web of Science ®Google Scholar